We have previously showed that GAD65-alum immunotherapy in T1D inadvertently expands bifunctional, potentially proinflammatory Th1/Th2 GAD65-specific CD4+ T cells28, partially explaining the lack of efficacy observed in the trial. This evidence concerns the gene CD4 and type 1 diabetes mellitus.